349-67-7

Basic information

• Product Name: 2-METHOXY-5-(TRIFLUOROMETHYL)PHENOL
• Synonyms: 2-METHOXY-5-(TRIFLUOROMETHYL)PHENOL
• CAS NO: 349-67-7
• Molecular Formula: C₈H₇F₃O₂
• Molecular Weight: 192.1351896
• Mol File: 349-67-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 104-105 °C(Press: 12 Torr)
• Appearance: /
• Density: 1.321±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.97±0.10(Predicted)
• CAS DataBase Reference: 2-METHOXY-5-(TRIFLUOROMETHYL)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-5-(TRIFLUOROMETHYL)PHENOL(349-67-7)
• EPA Substance Registry System: 2-METHOXY-5-(TRIFLUOROMETHYL)PHENOL(349-67-7)

Safety Data

• Hazardous Substances Data: 349-67-7(Hazardous Substances Data)

Usage

General Description

2-Methoxy-5-(trifluoromethyl)phenol is a chemical compound that consists of a phenol ring with a methoxy group and a trifluoromethyl group attached. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The trifluoromethyl group provides increased lipophilicity and metabolic stability, making it a valuable component in drug discovery and development. Additionally, the methoxy group can provide increased solubility and bioavailability in certain applications. The compound has potential uses in a variety of industries, including pharmaceuticals, agriculture, and material science. It is important to handle and use this chemical with care, as it may be hazardous if not properly managed.

Upstream product

• 402-52-8 methyl 4-(trifluoromethyl)phenyl ether 
• 240139-82-6 (2-methoxy-5-(trifluoromethyl)phenyl)boronic acid 

Downstream Products

• 344-67-2 2-methoxy-5-trifluoromethyl-hydroquinone 
• 366-10-9 4-nitro-benzoic acid-(2-methoxy-5-trifluoromethyl-phenyl ester) 
• 645-08-9 Isovanillic acid 
• 579-79-3 1-methoxy-2,5-bis-(4-nitro-benzoyloxy)-4-trifluoromethyl-benzene 

Relevant articles and documents

HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (l)-(ll l) or Compounds (1 )-(65) of Table 1 ) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotropic lateral sclerosis, glaucoma, ischaemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

New series of morpholine and 1,4-oxazepane derivatives as dopamine D 4 receptor ligands: Synthesis and 3D-QSAR model

Since the identification of the dopamine D43 receptor subtype and speculations about its possible involvement in schizophrenia, much work has been put into development of selective D4 ligands. These selective ligands may be effective antipsychotics without extrapyramidal side effects. This work describes the synthesis of a new series of 2,4-disubstituted morpholines and 2,4-disubstituted 1,4-oxazepanes with selectivity for the dopamine D4 receptor. A 3D-QSAR analysis using the GRID/GOLPE methodology was performed with the purpose to get a better understanding of the relationship between chemical structure and biological activity. Inspection of the coefficient plots allowed us to identify that regions which are important for affinity are situated around the two benzene ring systems, a p-chlorobenzyl group, and the aliphatic amine belonging to the morpholine or 1,4-oxazepane system. In addition, the size of the morpholine or 1,4-oxazepane ring seems to be important for affinity.